Early Insulin and Development of ARDS
Primary Purpose
Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Insulin
Sponsored by
About this trial
This is an interventional prevention trial for Respiratory Distress Syndrome, Adult focused on measuring Acute Respiratory Distress Syndrome, Acute Lung Injury
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with severe sepsis, which is defined as sepsis AND one or more signs of organ dysfunction or hypotension
- Hyperglycemia (i.e., glucose level greater than 130 mg/dL on one or more tests)
Exclusion Criteria:
- Diabetic ketoacidosis
- Severe chronic liver disease with Child-Pugh score greater than 10 (Class C)
- Documented episodes of blood or plasma glucose less than 60 mg/dL within 24 hours of study entry
- Lack of any available IV access for insulin infusion
- Pregnant
- Known advanced directives against intubation or aggressive ICU care
- Inability to be enrolled into the study in the 12 hours following admission to the ED
Sites / Locations
- Montefiore Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
Outcomes
Primary Outcome Measures
Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Secondary Outcome Measures
Murray Lung Injury Score
Murray Lung Injury Score is a continuous score that quantifies the severity of lung injury and consist of components related to severity of hypoxia, pulmonary compliance, peep, and radiologic abnormalities. The scores range between 0 - 4. The higher the score, the greater the degree and severity of lung injury. The scale runs from 0-4, with 0 being the minimum and 4 the maximum score.
Full Information
NCT ID
NCT00605696
First Posted
January 18, 2008
Last Updated
April 4, 2018
Sponsor
Albert Einstein College of Medicine
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT00605696
Brief Title
Early Insulin and Development of ARDS
Official Title
Early Insulin Therapy and Development of Acute Respiratory Distress Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
September 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Albert Einstein College of Medicine
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Symptoms usually develop within 24 to 48 hours of an original injury or illness, and people with ALI/ARDS typically require care in the intensive care unit (ICU). Little is known about how to prevent the onset of ALI/ARDS. The purpose of this study is to examine if early infusions of insulin, known as intensive insulin therapy (IIT), can help prevent ALI/ARDS in hospitalized patients with high levels of blood sugars and severe infections.
Detailed Description
ALI/ARDS is a life-threatening condition that involves inflammation of the lungs and fluid accumulation in the air sacs, leading to low blood oxygen levels and respiratory failure. Common causes include pneumonia, lung trauma, and sepsis, a condition that can lead to widespread inflammation and blood clotting in response to an infection. Recent studies have shown that insulin, which is regularly used to control blood sugar levels, may prevent or lessen the risk of lung tissue inflammation and/or lung injury related to sepsis. Research has shown that critically ill ICU patients often benefit from receiving insulin to target 80-110 mg/dl , but it is not known if insulin to target these levels can prevent the onset of ALI/ARDS. Therapies to prevent ALI/ARDS should occur early, preferably even prior to ICU admission, because at least 38% of people with ALI/ARDS are diagnosed with the condition once they reach the ICU. The purpose of this study is to determine whether insulin to target 80-110 mg/dl administered to critically ill patients in the emergency department (ED) is more beneficial at preventing ALI/ARDS than insulin to target 150-180 mg/dl after ICU admission.
This study will enroll people who are hospitalized with high blood sugar levels and severe sepsis. Participants will be randomly assigned to receive IIT within 6-12 hours of ED presentation to target 80-110 mg/dl or target 150-180 mg/dl for 48 hours after admission to the ICU followed by usual care. Prior to ICU admission and 1, 3, and 7 days after ICU admission, blood will be collected and analyzed for markers of inflammation and lung injury. Blood samples will be stored for future research studies. While participants are in the hospital, their medical records will be reviewed to gather information on medical and family history, demographics, vital signs, laboratory test results, x-ray findings, and lung function. Study researchers will also monitor participants for the development of severe lung failure or other organ failures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
Keywords
Acute Respiratory Distress Syndrome, Acute Lung Injury
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
Arm Title
2
Arm Type
Active Comparator
Arm Description
Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
Intervention Type
Drug
Intervention Name(s)
Insulin
Intervention Description
Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
Primary Outcome Measure Information:
Title
Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
Time Frame
Measured at Day 1, 3 and 7
Secondary Outcome Measure Information:
Title
Murray Lung Injury Score
Description
Murray Lung Injury Score is a continuous score that quantifies the severity of lung injury and consist of components related to severity of hypoxia, pulmonary compliance, peep, and radiologic abnormalities. The scores range between 0 - 4. The higher the score, the greater the degree and severity of lung injury. The scale runs from 0-4, with 0 being the minimum and 4 the maximum score.
Time Frame
Measured at Day 3
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with severe sepsis, which is defined as sepsis AND one or more signs of organ dysfunction or hypotension
Hyperglycemia (i.e., glucose level greater than 130 mg/dL on one or more tests)
Exclusion Criteria:
Diabetic ketoacidosis
Severe chronic liver disease with Child-Pugh score greater than 10 (Class C)
Documented episodes of blood or plasma glucose less than 60 mg/dL within 24 hours of study entry
Lack of any available IV access for insulin infusion
Pregnant
Known advanced directives against intubation or aggressive ICU care
Inability to be enrolled into the study in the 12 hours following admission to the ED
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Ng Gong, MD, MS
Organizational Affiliation
Montefiore Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Early Insulin and Development of ARDS
We'll reach out to this number within 24 hrs